A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma.

Trial Profile

A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2015

At a glance

  • Drugs Pelareorep (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 06 Jul 2015 According to Oncolytics Biotech media release, final data has been presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.
    • 06 Jul 2015 Results published in Oncolytics Biotech Media Release.
    • 29 May 2015 Results of the correlation of outcomes with skeletal muscle changes were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top